title: Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
abstract: Glatiramer acetate (GA), a synthetic copolymer, is a frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Probable autoimmune hepatotoxicity during GA treatment has been reported,(1-4) but GA hepatotoxicity in the absence of positive autoimmune markers has not previously been described. Here, we report GA-induced hepatotoxicity in a pediatric patient with multiple sclerosis (MS).
authors.affiliation: Hospital for Sick Children, Canada. Naila.makhani@sickkids.ca
authors.forename: Naila
authors.initials: N
authors.lastname: Makhani
authors.forename: Bo-yee
authors.initials: BY
authors.lastname: Ngan
authors.forename: Binita M
authors.initials: BM
authors.lastname: Kamath
authors.forename: E Ann
authors.initials: EA
authors.lastname: Yeh
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000627:therapeutic use; D000293:Adolescent; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate